Loading patent…
AssigneeZymoGenetics, Inc.
InventorsWayne R. Kindsvogel, Steven D. Hughes, Richard D. Holly, Christopher H. Clegg, Donald C. Foster, Rebecca A. Johnson, Mark D. Heipel, Pallavur V. Sivakumar
Estimating the term…
Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies.
A method of treating cancer in a subject comprising co-administering a therapeutically effective amount of an anti-CD-20 monoclonal antibody wherein said CD-20 is murine or human and a therapeutically effective amount of an IL-21 polypeptide comprising a sequence of amino acids as shown in SEQ ID NO:2 from amino acid residue 30 to residue 162, wherein the anti-CD-20 monoclonal antibody and IL-21 polypeptide are administered once weekly for up to eight consecutive weeks and the IL-21 polypeptide dose is from 100 to 300 μg/kg/dose.
A method of treating cancer in a subject comprising co-administering a therapeutically effective amount of rituximab and a therapeutically effective amount of an IL-21 polypeptide comprising a sequence of amino acids as shown in SEQ ID NO:2 from amino acid residue 30 to residue 162, wherein the rituximab and IL-21 polypeptide are administered once weekly for up to eight consecutive weeks and the IL-21 polypeptide dose is from 100 to 300 μg/kg/dose.
Dependencies are inferred from the claim text.